140P Benefit of adjuvant chemotherapy in luminal A-like early breast cancer in women aged 40 years or younger: Results of a national multi-institutional study

Abstract

Young age is a poor prognosis factor in early-stage breast cancer (BC), regardless of molecular subtype or stage at diagnosis. Yet, evidence to support adjuvant chemotherapy in luminal A-like patients aged 40 years or younger is limited. The primary objective of this study was to examine the impact of adjuvant chemotherapy (aCT) on outcomes in this population.